CJC1295 DAC 5mg
$69.99
CJC-1295 with DAC is a synthetic peptide that stimulates the release of growth hormone. Acting as a growth hormone-releasing hormone (GHRH) analog, CJC-1295 with DAC prolongs the half-life and efficacy of growth hormone release, enhancing overall hormone production. It’s widely researched for its potential in increasing muscle mass, improving immune function, and promoting recovery and wellness. This compound is of significant interest in sports medicine, anti-aging therapy, and among bodybuilding communities for its purported benefits on physical performance and health rejuvenation.
Availability: Ships today if ordered and paid by 7AM EST
Where to buy CJC-1295 with DAC? Shop now for CJC-1295 with DAC with exceptional quality and get more for less with our bulk sales. Quick 48-hour delivery available.
CJC-1295 DAC 5mg Properties
Chemical Formula: C152H252N44O42
Molecular Mass: 3647.28
Synonyms: CJC1295 Without DAC, CJC1295 With DAC, 446262-90-4
Molar Mass: 3367.9
CAS Number: 446036-97-1
PubChem: 91976842
Total Amount of the Active Ingredient: 2mg (1 vial)
Shelf Life: 36 months
Product Quality
Lab tests are occasionally published on the website. You can have the product you bought from us tested at any HPLC licensed testing facility and if the results are negative, we will refund the following:
Cost of HPLC test
Total amount of the order + shipping fee
Peer-Reviewed Studies
Abstract
Context: Therapeutic use of GHRH to enhance GH secretion is limited by its short duration of action.
Objective: The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting GHRH analog.
Design: The study design was two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 d.
Setting: The study was performed at two investigational sites.
Participants: Healthy subjects, ages 21–61 yr, were studied.
Interventions: CJC-1295 or placebo was administered sc in one of four ascending single doses in the first study and in two or three weekly or biweekly doses in the second study.
Main Outcome Measures: The main outcome measures were peak concentrations and area under the curve of GH and IGF-I; standard pharmacokinetic parameters were used for CJC-1295.
Results: After a single injection of CJC-1295, there were dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9–11 d. The estimated half-life of CJC-1295 was 5.8–8.1 d. After multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 d. No serious adverse reactions were reported.
Conclusions: Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 μg/kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC-1295 as a therapeutic agent.
Abstract
Although the majority of children with isolated growth hormone (GH) deficiency have a good growth response to GH-releasing hormone (GHRH), the use of this therapeutic agent is limited by its very short half-life. Indeed, we have shown that, in mice with GHRH gene ablation (GHRH knockout; GHRHKO), even twice-daily injections of a GHRH analog are unable to normalize growth. CJC-1295 is a synthetic GHRH analog that selectively and covalently binds to endogenous albumin after injection, thereby extending its half-life and duration of action. We report the effects of CJC-1295 administration in GHRHKO animals. Three groups of 1-wk-old GHRHKO mice were treated for 5 wk with 2 μg of CJC-1295 at intervals of 24, 48, and 72 h. Placebo-treated GHRHKO mice and mice heterozygous for the GHRHKO allele served as controls. GHRHKO animals receiving daily doses of CJC-1295 exhibited normal body weight and length. Mice treated every 48 and 72 h reached higher body weight and length than placebo-treated animals, without full growth normalization. Femur and tibia length remained normal in animals treated every 24 and 48 h. Relative lean mass and subcutaneous fat mass were normal in all treated groups. CJC-1295 caused an increase in total pituitary RNA and GH mRNA, suggesting that proliferation of somatotroph cells had occurred, as confirmed by immunohistochemistry images. These findings demonstrate that treatment with once-daily administration of CJC-1295 is able to maintain normal body composition and growth in GHRHKO mice. The same dose is less effective when administered every 48 or 72 h.
Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions
Abstract
Background: Communal online folk pharmacology fuels the drive for short cuts in attaining muscle enhancement, fat loss, and youthful skin.
Objectives: The study used “netnography” to explore female use of CJC-1295, a synthetic growth hormone analogue from the perspectives contained in Internet forum activity.
Methods: A systematic Internet search was conducted using variation of the term “CJC-1295”; and combined with “forum.” Ninety-six hits related to bodybuilding websites where CJC-1295 was mentioned. Following application of exclusion criteria to confine to female use and evidence of forum activity, 9 sites remained. These were searched internally for reference to CJC-1295. Twenty-three discussion threads relating to female use of CJC-1295 formed the end data set, and analyzed using the Empirical Phenomenological Psychological method.
Results: Forum users appeared well versed and experienced in the poly use of performance and image drug supplementation. Choice to use CJC-1295 centered on weight loss, muscle enhancement, youthful skin, improved sleep, and injury healing. Concerns were described relating to female consequences of use given gender variations in growth hormone pulses affecting estimation of dosage, cycling, and long-term consequences.
Conclusions: Public health interventions should consider female self-medicating use of synthetic growth hormone within a repertoire of product supplementation, and related adverse health consequences.
Shipping
USA
Canada
If your shipment was seized (International Orders), we will provide a 50% discount applicable on your next purchase. Please contact us for more information.
Disclaimer
The information provided above is not intended to substitute medical advice, diagnosis, or treatment. Should you have any questions regarding a medical condition, seek the advice of your physician or a qualified healthcare provider. In no case should medical advice be disregarded or delayed because of what you have read or seen. We bear no responsibility or liability for your use of any of our research compounds and products. Please note that they are being sold for research purposes ONLY. We do NOT condone any personal use.
Note: In some cases wherein the assigned top colors are out of stock, a different top color will be used to ensure that your order will not be delayed. Should you need assistance identifying the peptide vial that you received, please send us an email at [email protected].
By purchasing from AMERICAN RESEARCH, you agree that you are purchasing Research Chemicals. AMERICAN RESEARCH products are furnished for LABORATORY RESEARCH USE ONLY.
This product should only be handled by qualified and licensed professionals. The product may not be used as a drug, agricultural or pesticide product, food additive, or household chemical – and may not be misbranded as such. All information on this website is available for educational purposes only. Bodily introduction of any kind into humans and/or animals is strictly forbidden by law.
*Research chemicals are chemical substances used by scientists for medical and scientific research purposes. One characteristic of a research chemical is that it is for laboratory research use only; a research chemical is not intended for human or veterinary use. This distinction is required on the labels of research chemicals and is what exempts them from regulation under parts 100-740 in Title 21 of the Code of Federal Regulations (21CFR).
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: "in glass") are performed outside the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat and/or cure any medical condition, ailment or disease. Bodily introduction of any kind into animals or human is strictly prohibited by law.
Additional information
| Weight | 0.5 lbs |
|---|---|
| Title | Default Title |
FAQ
CJC 1295 with DAC 5mg Vials
How to reconstitute CJC 1295 with DAC 5mg vials?
CJC 1295 with DAC 5mg vials contain a peptide powder, which is typically a puck or loose bits due to shipping. To reconstitute a CJC 1295 with DAC 5mg vials, researchers typically use bacteriostatic water, combining it with the peptide powder according to the specific requirements of their research protocols.
How to dose CJC 1295 with DAC 5mg?
The dosing of CJC 1295 with DAC 5mg in vials form will vary according to the experiment being conducted. We do not provide dosage recommendations as our products are intended for research purposes only.
How to administer CJC 1295 with DAC 5mg?
There are multiple methods of administering research products that are under investigation in various studies. The choice of administration technique should align with the specific goals and design of the researcher’s study. We provide products solely for research use, we do not offer advice on administration methods.
